Antibody-Drug Conjugates

Antibody-Drug Conjugates, or ADCs, are purposefully designed to deliver cytotoxins to cancer cells with the potential to treat both solid tumors and hematologic cancers.

MECHANISM OF ACTION

ADCs use a chemical linker to connect cytotoxins with an antibody. The specificity of the antibody enables the ADC to target and bind to cell-surface proteins called antigens that can be found on cancer cells and release its cell-killing drugs only after it has been internalized by the cancer cell. As a result, ADCs have the potential to selectively kill cancer cells.

PFIZER ADC PORTFOLIO

Pfizer is using its understanding of the biology of cancer to explore a number of antibody-linker-cytotoxin combinations and build proprietary ADC platforms using a diverse array of ADC design components.

INVESTIGATIONAL ASSET

PF-06647020 is a novel ADC candidate targeting PTK7, a receptor tyrosine kinase expressed in many tumor types and associated with poor prognosis.¹

REFERENCE